喉鳞癌组织MAGEA1和MAGEA3蛋白表达及其生物学意义的研究

Expression and clinical significance of MAGEA1 and MAGEA3 protein in human laryngeal squamous carcinoma tissues

目的:检测黑色素瘤抗原基因MAGEA1和MAGEA3在喉鳞癌组织中的表达,探讨其作为喉癌免疫治疗靶标的可行性及其与喉癌生物学行为的关系。方法:采用免疫组化PV9000两步法检测69例喉鳞癌原发灶及其常规病理报告为阳性的121枚颈淋巴结中MAGEA1和MAGEA3的表达,同时采用蛋白质印迹法检测其在喉癌标本的癌中心区(TC),癌周0.5和1.0 cm及9例喉正常黏膜组织中的表达,并结合临床病理资料进行分析。结果:69例喉鳞癌组织中,MAGEA1蛋白的阳性表达率为58.0%(40/69),MAGEA3蛋白的阳性表达率为29.0%(20/69)。两种蛋白在癌中心区,癌周0.5和1.0 cm区中的表达逐渐下降(P<0.05),9例喉正常黏膜组织中无表达。MAGEA1和MAGEA3表达与肿瘤的T分期无关(P>0.05),MAGEA1蛋白的表达与病理分级相关(P<0.05),伴淋巴结转移的患者MAGEA3的表达率高于未转移者(P<0.05),颈转移淋巴结中两种蛋白的表达均下调。结论:MAGEA1和MAGEA3在喉鳞癌组织中特异高表达,可能以某种方式参与了喉癌的发生、发展,是进行喉癌免疫治疗的理想靶分子之一。

OBJECTIVE： To detect the expression of melanoma antigen A1 （MAGEA1） protein and melanoma antigen A3 （MAGEA3） protein in human laryngeal squamous carcinoma （LSC）, and explore its significance in immunotherapeutic application. METHODS： The expressions of MAGEA1 and MAGEA3 protein in 69 laryngeal squamous carcinoma eases and 121 pathologically positive lymph nodes were detected by PV9000 immuno histochemistry. Western-blot was used to measure the expressions in the tumor core region（TC）, the tissues at the sites of 0.5 and 1.0 cm away from LSC periphery and the distant normal larynx tissues. RESULTS： The positive expression rates of MAGEA1 and MAGEA3 were 58.0%（40/69） and 29.0%（20/69）. The expression levels of two kinds of MAGE protein were found to signifi cantly decrease by turns in TC and corresponding adjacent tissues （0.5 and 1.0 cm from focus, P〈0.05）. None of the nine normal larynx tissues expressed them. It did not display an obvious correlation between the expression of MAGE with T staging （P 〉 0.05）. The expression of MAGEA1 was significantly related to the pathological grading （P〈0.05）, and the expression of MAGEA3 in the cases with cervical lymph node metastasis was significantly higher than those without lymph node metastasis （P 〈 0. 05 ）. CONCLUSION： MAGEA1 and MAGEA3 protein are expressed at high level in human LSC, and they may play a role in genesis and development of tumors, which suggests that these two genes may be used as target antigens for immunotherapy of LSC.